Tradestie Institutional Equity Comparison Engine

CRMD vs DRTS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRMD Overall Edge

CRMD Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while DRTS counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRMD trades at 29.5x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus DRTS at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRMD sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro) against DRTS sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRMD
CRMD 29.5x vs DRTS N/M Fwd P/E
Growth & Margin Winner CRMD
Op Margin 41.0% vs 0.0% ยท YoY -47.7% vs +0.0%
Momentum & Technical Winner DRTS
1Y -58.2% vs +223.9% ยท 52W Pos 1% vs 70%
Options & Structure Winner DRTS
BREAKDOWN (22nd %ile IV) vs CONSOLIDATION (25th %ile IV)
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.70
-2.59% 1D
Market Cap $370.6M
1M Return -36.38%
1Y Return -58.23%
Forward P/E 29.5x
Unified AI Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0
DRTS NASDAQ
Alpha Tau Medical Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$12.03
+0.5% 1D
Market Cap $1.2B
1M Return -4.68%
1Y Return +223.91%
Forward P/E N/M
Unified AI Score
43.3 / 100 HOLD
Tech 35.0 Fund 54.0 Flow 71.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRMD -58.23% DRTS +223.91% Spread: +282.14 pp (DRTS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRMD TTM Op. Margin: 41.0% DRTS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs DRTS. Trailing 12-month operating profitability (CRMD 41.0% vs DRTS 0.0%) and valuation multiples (CRMD 29.5x vs DRTS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRMD (6) vs DRTS (4)
Institutional Metric CRMD DRTS Criterion Row Winner
Market Capitalization Scale $370.6M $1.2B Larger Scale DRTS
Trailing P/E Ratio Valuation 2.4x N/M Lower Multiple CRMD
Forward P/E Ratio Valuation 29.5x N/M Lower Multiple CRMD
Revenue Growth (YoY) Growth -47.7% +0.0% Higher Growth DRTS
Operating Margin (TTM) Profitability 41.0% 0.0% Higher Margin CRMD
Net Profit Margin Profitability 15.5% 0.0% Higher Margin CRMD
Return on Equity (ROE) Capital Efficiency 15.3% -141.7% Higher ROE CRMD
52-Week Range Position Momentum 1% ($5โ€“$13) 70% ($3โ€“$16) Stronger Trend DRTS
Beta / 30D Volatility Risk Regime 1.22ฮฒ ยท 103% Vol 1.71ฮฒ ยท 62% Vol Lower Realized Risk DRTS
Unified Institutional Score Composite Signal 55.5 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite CRMD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRMD vs DRTS Buy Guide
CRMD BREAKDOWN
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live CRMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DRTS CONSOLIDATION
95d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live DRTS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRMD nor DRTS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.